Do you want to skip to content? Skip to content
Contact Us Convatec.com Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
False /oidc-signin/en-us/ Contact Us Convatec.com Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Convatec expands support for people living with advanced Parkinson´s disease

Convatec’s Neria™Guard infusion device is used for continuous subcutaneous infusion of a number of drugs for patients on infusion pump

London, UK, 11 January – Convatec, a leading medical products and technologies company, is pleased to announce a significant step forward for people living with advanced Parkinson´s disease.

The worldwide population living with Parkinson´s, a disease leading to disability and affecting quality of life1,2, is estimated to be 10 million3. Consistent with our ‘forever caring’ promise, we are pleased to announce the expanded use of our technology further for people living with Parkinson´s disease with the use of our Neria™Guard subcutaneous infusion set for apomorphine and Foslevodopa-foscarbidopa.

This is a significant step towards providing more subcutaneous drug delivery options for certain groups of patients where this treatment is an option aligned with their healthcare professional. Convatec has been able to achieve this milestone by partnering with pharma companies that are launching their drugs together with Neria™Guard infusion set.

Neria™Guard is an all-in-one infusion set with fully automatic insertion at the touch of a button4 that can make it easier to use especially for those with dexterity issues5. The set connects to a pump on one end and the user’s infusion site on the other end. The retractable needle can provide increased comfort* during insertion of the soft cannula5 and can help prevent accidental needle-stick incidents4. Neria™Guard's easy and intuitive insertion technique4 protects against insertion technique errors4 and can encourage independence in patients’ everyday lives in agreement with their healthcare professional.5

*compared to a steel needle.

Convatec’s Neria™Guard infusion set will now also be used with Foslevodopa-foscarbidopa in selected EU countries.

Kjersti Grimsrud, President & Chief Operating Officer, Infusion Care said, “We are pleased to be able to support people living with chronic disease in more markets and give more treatment options using our innovative Neria™Guard infusion set. This demonstrates the strength of Convatec’s leadership in subcutaneous infusion solutions as we continue to provide innovation to people living with chronic diseases beyond diabetes”.

References:

1. Fasano, A., Fung, V.S.C., Lopiano, L. et al. (2019). Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 19 (1), 50.

2. Barone, P., Antonini, A., and Colosimo et al. (2009). The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 24 (11), 1641–1649.

3. https://www.parkinsonseurope.org/about-parkinsons/what-is-parkinsons/; Accessed November 30, 2023.

4. Convatec Data on File, Unomedical A/S, 2023. (D012-002912)

5. Hillman E. (2020). Examining the use of sharp-free subcutaneous infusion devices with apomorphine. British Journal of Neuroscience Nursing, 16 (4), 5.

Contact
Investor Relations: IR@convatec.com   
Media: MediaRelations@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com 

For information about Neria™Guard, please refer to the instructions for use that come with the product.

Press Release

See all

14-Nov-24

Corporate

logo, company name

Convatec responds to Local Coverage Determinations (LCDs) on skin substitutes

Read more

12-Nov-24

Corporate

Financial Performance

logo, company name

Trading update for the ten months ended 31 October 2024

Convatec upgrades FY24 guidance; on-track for double-digit EPS growth in 2024 and 2025

Read more

21-Oct-24

Corporate

Infusion Care

logo, company name

Convatec collaborates with AbbVie for VYALEV™ therapy for the treatment of advanced Parkinson’s disease in the United States

Convatec’s Neria™ Guard will be used to deliver AbbVie’s VYALEV™ therapy (foscarbidopa and foslevodopa) in the United States, following FDA approval

Read more

10-Oct-24

Corporate

Advanced Wound Care

logo, company name

Convatec update on InnovaMatrix® AC clinical data – second randomised controlled trial authorised

Convatec continues to advance clinical evidence for InnovaMatrix® AC

Read more

20-Sep-24

Corporate

Advanced Wound Care

logo, company name

Convatec update on InnovaMatrix® AC clinical data

InnovaMatrix® AC is a pioneering technology in the treatment of wounds

Read more

21-Aug-24

Corporate

Continence Care

logo, company name

Comment on the announcement of CMS changes to catheter codes

Read more

01-Aug-24

Continence Care

graphical user interface, application

Convatec me+ Companion™ App offers support for millions of intermittent catheter users

New free app offers users a practical tool to ensure their cathing journey starts smoothly

Read more

30-Jul-24

Corporate

Financial Performance

logo, company name

Interim Results for the six months ended 30 June 2024

Strong broad-based revenue growth and further strategic progress

Read more

26-Jul-24

Continence Care

a few different colored pencils

Convatec’s pioneering catheter for women continues to scale up in Europe

The new compact offering blends gentle, protective cathing with everyday discretion and ease of use.

Read more

16-May-24

Corporate

Financial Performance

a person holding a person's hand while he is holding a coat

AGM trading update for the four months ended 30 April 2024

Revenue continued to build, further strategic progress, on track to deliver financial guidance

Read more

01-May-24

Advanced Wound Care

text, application, Word

Convatec unveils significant advanced wound care clinical study results

New research demonstrates superiority of AQUACEL® Ag+ Extra™ dressing in the management of venous leg ulcers

Read more

26-Apr-24

Corporate

logo, company name

Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

Read more

06-Mar-24

Corporate

Financial Performance

a hand holding a light bulb

Annual Results for the twelve months ended 31 December 2023

Read more

29-Feb-24

Ostomy Care

a woman holding a shoe

Convatec launches new Esteem Body™ with Leak Defense™

Read more

11-Jan-24

Infusion Care

icon

Convatec expands support for people living with advanced Parkinson´s disease

Read more